Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Diabetes Obes Metab ; 11(11): 1027-33, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19614945

RESUMO

AIM: Compare the response to oral glucose of the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) at 1 year after restrictive vs. malabsorptive bariatric surgery. METHODS: Vertical banded gastroplasty (VBG, n = 7) or jejunoileal bypass (JIB, n = 5) was performed in 12 women, aged 26-39 years, with severe obesity [body mass index (BMI) 46.6 +/- 2.3 kg/m(2)]. After 1 year, 75 g glucose was administered and plasma levels of glucose, insulin, GIP and GLP-1 were determined regularly during the following 2 h. RESULTS: At 1 year after operation, reduction in body weight, actual body weight, fasting glucose or insulin, or the glucose and insulin responses to oral glucose did not differ significantly between the groups. Similarly, fasting GIP and GLP-1 levels did not differ significantly between the groups. In contrast, the GIP and GLP-1 responses to oral glucose were different between the groups in a dissociated pattern. Thus, AUC(GIP) was significantly higher after VBG than after JIB (53 +/- 8 vs. 26 +/- 6 pmol/l/min, p = 0.003). In contrast, AUC(GLP-1) was significantly higher after JIB than after VBG (49 +/- 5 vs. 20 +/- 3 pmol/l/min, p = 0.007). CONCLUSIONS: We conclude that at 1 year after bariatric surgery, the two incretins show dissociated responses in that the GIP secretion is higher after VBG whereas GLP-1 secretion is higher after JIB. This dissociated incretin response is independent from reduction in body weight, glucose tolerance or insulin secretion.


Assuntos
Cirurgia Bariátrica , Polipeptídeo Inibidor Gástrico/sangue , Peptídeo 1 Semelhante ao Glucagon/sangue , Incretinas/sangue , Obesidade Mórbida/sangue , Adulto , Feminino , Polipeptídeo Inibidor Gástrico/metabolismo , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Humanos , Obesidade Mórbida/cirurgia , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento
2.
Adv Ther ; 24(2): 439-47, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17565935

RESUMO

This study was undertaken to compare the effects on plasma cholesterol concentration of a new isolated soy protein in which the protein structure is kept in its native, nondenaturated form (verum 1) versus a conventional isolated soy protein (verum 2) and milk protein (placebo). This prospective, randomized, double-blind, placebo-controlled study was conducted in an outpatient clinical study center in Berlin, Germany. Over 8 wk, 120 patients (total cholesterol, 5.2-7.8 mmol/L) were given verum 1, verum 2, or placebo at a dosage of 25 g protein daily. At the end of the treatment period, total cholesterol levels were significantly reduced by 10.7% in the verum 1 group compared with placebo (P<.001), and levels were reduced by 5.8% in the verum 2 group (P=.008). The difference between the 2 verum groups was statistically significant (P=.008). Low-density lipoprotein cholesterol levels were significantly reduced with nondenaturated isolated soy protein only: levels were reduced by 9.4% in the verum 1 group (P=.002) and by 4.9% in the verum 2 group (P=.107). Again, the difference between the verum groups was significant (P=.05). The results of this study confirm that supplementation with isolated soy protein can lead to significant reductions in plasma concentrations of total and low-density lipoprotein cholesterol. These reductions are significantly more pronounced with an isolated soy protein that maintains the native protein structure than with a commercially available reference isolated soy protein.


Assuntos
Anticolesterolemiantes/uso terapêutico , Colesterol/sangue , Hipercolesterolemia/tratamento farmacológico , Proteínas de Soja/uso terapêutico , Adulto , Idoso , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas do Leite/farmacologia , Estudos Prospectivos
3.
Diabetes Metab ; 28(6 Pt 1): 448-56, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12522324

RESUMO

OBJECTIVE: Our aim was to distinguish beneficial effects of B-cell rest from other effects of correction of hyperglycaemia. For this purpose we used diazoxide which reversibly blocks insulin secretion. MATERIAL AND METHODS: Eight obese (age 53 +/- 1 yr: BMI 33 +/- 2 kg/m2: 4 females) type 2 diabetic patients with poor metabolic control (HbA1c 8.7 +/- 0.9% ref.<5.2%) were studied twice after a randomly ordered treatment period of five days of intensive i.v. insulin treatment alone or i.v. insulin with peroral diazoxide (300 mg/day, divided into 3 doses). The glycaemic control was not altered between the two treatment periods. Insulin secretion was measured in response to i.v. glucose and arginine. RESULTS: Insulin infusion was used to achieve close to identical degrees of glycaemia during the two treatment periods. Previous treatment with diazoxide was associated with a moderate 1.9 +/- 0.6 fold rise in insulin response to intravenous glucose (p=0.04) and 1.6 +/- 0.4 fold increased glucose potentiation of arginine-induced insulin secretion (GPAIS) (p=0.04). Conversely, after insulin alone there was no response to i.v. glucose and no change in GPAIS. CONCLUSIONS: Short-term diazoxide treatment improved important parameters of B-cell function and these effects could be dissociated from confounding effects of changes in glycaemia. Consequently, the results indicate beneficial effects of B-cell rest.


Assuntos
Glicemia/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus/tratamento farmacológico , Diazóxido/uso terapêutico , Insulina/metabolismo , Insulina/uso terapêutico , Ilhotas Pancreáticas/metabolismo , Obesidade , Anti-Hipertensivos/uso terapêutico , Glicemia/efeitos dos fármacos , Peptídeo C/sangue , Colesterol/sangue , LDL-Colesterol/sangue , Quimioterapia Combinada , Hemoglobinas Glicadas/metabolismo , Humanos , Hipoglicemiantes/uso terapêutico , Infusões Intravenosas , Insulina/administração & dosagem , Insulina/sangue , Secreção de Insulina , Ilhotas Pancreáticas/efeitos dos fármacos , Pessoa de Meia-Idade , Proinsulina/sangue , Análise de Regressão , Triglicerídeos/sangue
4.
Diabetes Obes Metab ; 1(1): 53-5, 1999 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11221813

RESUMO

AIM: To explore whether the lowering of insulin relates to changes in leptin following weight reduction after vertical banded gastroplasty (VBG) in seven grossly obese women (BMI 45.9 +/- 1.5 kg/m2). RESULTS: At 6-24 months after VBG, BMI was reduced to 31.3 +/- 0.9 kg/m2 (p < 0.018), leptin from 43 +/- 9 to 12 +/- 2 ng/ml (p < 0.018) and insulin from 172 +/- 19 to 71 +/- 2 pmol/l (p=0.018). The reduction in leptin correlated to the reduction in insulin (r = 0.94, p = 0.002) but not to that of BMI (r = 0.05, NS). CONCLUSION: Reduction in insulin seems more important for reduction in leptin than lowering of BMI, suggesting a close association between leptin and insulin in obese subjects.


Assuntos
Gastroplastia , Insulina/sangue , Leptina/sangue , Obesidade/sangue , Obesidade/cirurgia , Redução de Peso , Adulto , Índice de Massa Corporal , Feminino , Gastroplastia/métodos , Humanos , Pessoa de Meia-Idade , Período Pós-Operatório
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA